Next generation drug-eluting stents: Focus on bioabsorbable platforms and polymers

Medical Devices: Evidence and Research

Volumn 2, Issue 1, 2009, Pages 47-55

  Doyle, Brendan ^a   Holmes Jr , David R ^a  

^a Mayo Clinic College of Medicine   (United States)

Author keywords

Bioabsorbable; Biodegradable; Percutaneous coronary intervention; Polymer; Stent

Indexed keywords

BIOABSORBABLE; BIOABSORBABLE POLYMER; BIODEGRADABLE; CORONARY ARTERY DISEASE; DRUG-ELUTING STENTS; ECONOMIC COSTS; LONG-TERM SAFETY; PERCUTANEOUS CORONARY INTERVENTION; PERCUTANEOUS TREATMENT; RESTENOSIS; STENT DESIGN; TECHNICAL ADVANCES;

ARTIFICIAL ORGANS; COST REDUCTION; DISEASES; DRUG THERAPY;

BIODEGRADABLE POLYMERS;

ANTITHROMBOCYTIC AGENT; BVS; CYPHER; ESTRADIOL; EVEROLIMUS; FIBRIN; IGAKI TAMAI; NEVO; PACLITAXEL; POLYGLACTIN; POLYMER; RAPAMYCIN; REVA; UNCLASSIFIED DRUG; ZOTAROLIMUS;

ANGIOCARDIOGRAPHY; ANTICOAGULANT THERAPY; BARE METAL STENT; BIODEGRADABILITY; BIOSORPTION; CELL INFILTRATION; CLINICAL PRACTICE; CLINICAL TRIAL; COHORT ANALYSIS; CORONARY ARTERY DISEASE; CORONARY BLOOD VESSEL; COST OF ILLNESS; DISEASE ASSOCIATION; DISEASE EXACERBATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG ELUTING STENT; DRUG MEGADOSE; DRUG RELEASE; FOLLOW UP; HEALING IMPAIRMENT; HEART INFARCTION; HISTOLOGY; HUMAN; IN-STENT RESTENOSIS; INFLAMMATORY CELL; MORBIDITY; MORTALITY; NONHUMAN; PATIENT SAFETY; PERCUTANEOUS CORONARY INTERVENTION; QUANTITATIVE ANALYSIS; REVASCULARIZATION; REVIEW; RISK ASSESSMENT; SCANNING ELECTRON MICROSCOPY; STENT THROMBOSIS;

EID: 77953453062     PISSN: None     EISSN: 11791470     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Ako J, Morino Y, Honda Y, et al. Late incomplete stent apposition after sirolimus-eluting stent implantation: a serial intravascular ultrasound analysis. J Am Coll Cardiol. 2005;46(6):1002-1005.
2. Joner M, Finn AV, Farb A, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol. 2006;48(1):193-202.
3. Kotani J, Awata M, Nanto S, et al. Incomplete neointimal coverage of sirolimus-eluting stents: angioscopic findings. J Am Coll Cardiol. 2006;47(10):2108-2111.
4. Sousa JE, Serruys PW, Costa MA. New frontiers in cardiology: drugeluting stents: Part I. Circulation. 2003;107(17):2274-2279.
5. Virmani R, Guagliumi G, Farb A, et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation. 2004;109(6):701-705.
6. Camenzind E, Steg PG, Wijns W. Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern. Circulation. 2007;115(11):1440-1455; discussion 1455.
7. Pfisterer M, Brunner-La Rocca HP, Buser PT, et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol. 2006;48(12):2584-2591.
8. Tsimikas S. Drug-eluting stents and late adverse clinical outcomes lessons learned, lessons awaited. J Am Coll Cardiol. 2006;47(10):2112- 2115.
9. Doyle B, Rihal CS, O'Sullivan CJ, et al. Outcomes of stent thrombosis and restenosis during extended follow-up of patients treated with baremetal coronary stents. Circulation. 2007;116(21):2391-2398.
10. John MC, Wessely R, Kastrati A, et al. Differential healing responses in polymer- and nonpolymer-based sirolimus-eluting stents. JACC Cardiovasc Interv. 2008;1(5):535-544.
11. Carter AJ, Aggarwal M, Kopia GA, et al. Long-term effects of polymer-based, slow-release, sirolimus-eluting stents in a porcine coronary model. Cardiovasc Res. 2004;63(4):617-624.
12. Finn AV, Kolodgie FD, Harnek J, et al. Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus - or paclitaxel-eluting stents. Circulation. 2005;112(2):270-278.
13. Hoye A, Iakovou I, Ge L, et al. Long-term outcomes after stenting of bifurcation lesions with the "crush" technique: predictors of an adverse outcome. J Am Coll Cardiol. 2006;47(10):1949-1958.
14. Kuchulakanti PK, Chu WW, Torguson R, et al. Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents. Circulation. 2006;113(8):1108-1113.
15. Takano M, Ohba T, Inami S, Seimiya K, Sakai S, Mizuno K. Angioscopic differences in neointimal coverage and in persistence of thrombus between sirolimus-eluting stents and bare metal stents after a 6-month implantation. Eur Heart J. 2006;27(18):2189-2195.
16. Byrne RA, Mehilli J, Iijima R, et al. A polymer-free dual drug-eluting stent in patients with coronary artery disease: a randomized trial vs polymer-based drug-eluting stents. Eur Heart J. 2009;30(8):923-931.
17. Byrne RA, Iijima R, Mehilli J, et al. Durability of antirestenotic efficacy in drug-eluting stents with and without permanent polymer. JACC Cardiovasc Interv. 2009;2(4):291-299.
18. Finn AV, Nakazawa G, Joner M, et al. Vascular responses to drug eluting stents: importance of delayed healing. Arterioscler Thromb Vasc Biol. 2007;27(7):1500-1510.
19. Han Y, Jing Q, Chen X, et al. Long-term clinical, angiographic, and intravascular ultrasound outcomes of biodegradable polymercoated sirolimus-eluting stents. Catheter Cardiovasc Interv. 2008;72(2):177-183.
20. Windecker S, Serruys PW, Wandel S, et al. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial. Lancet. 2008;372(9644):1163-1173.
21. Onuma Y, Serruys P, den Heijer P, et al. MAHOROBA, first-in-man study: 6-month results of a biodegradable polymer sustained release tacrolimus-eluting stent in de novo coronary stenoses. Eur Heart J. 2009 Jun;30(12):1477-1485.
22. Krucoff MW, Kereiakes DJ, Petersen JL, et al. A novel bioresorbable polymer paclitaxel-eluting stent for the treatment of single and multivessel coronary disease: primary results of the COSTAR (Cobalt Chromium Stent With Antiproliferative for Restenosis) II study. J Am Coll Cardiol. 2008;51(16):1543-1552.
23. van der Giessen WJ, Sorop O, Serruys PW, Peters-Krabbendam I, van Beusekom HM. Lowering the dose of sirolimus, released from a nonpolymeric hydroxyapatite coated coronary stent, reduces signs of delayed healing. JACC Cardiovasc Interv. 2009;2(4):284-290.
24. Stack RS, Califf RM, Phillips HR, et al. Interventional cardiac catheter izat ion at Duke Medical Center. Am J Cardiol. 1988;62(10 Pt 2):3F-24F.
25. van der Giessen WJ, Lincoff AM, Schwartz RS, et al. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation. 1996;94(7):1690-1697.
26. Venkatraman S, Poh TL, Vinalia T, Mak KH, Boey F. Collapse pressures of biodegradable stents. Biomaterials. 2003;24(12):2105-2111.
27. Uurto I, Juuti H, Parkkinen J, et al. Biodegradable self-expanding poly-L/D-lactic acid vascular stent: a pilot study in canine and porcine iliac arteries. J Endovasc Ther. 2004;11(6):712-718.
28. Vogt F, Stein A, Rettemeier G, et al. Long-term assessment of a novel biodegradable paclitaxel-eluting coronary polylactide stent. Eur Heart J. 2004;25(15):1330-1340.
29. Asplund B, Sperens J, Mathisen T, Hilborn J. Effects of hydrolysis on a new biodegradable co-polymer. J Biomater Sci Polym Ed. 2006;17(6):615-630.
30. Ramcharitar S, Serruys PW. Fully biodegradable coronary stents: progress to date. Am J Cardiovasc Drugs. 2008;8(5):305-314.
31. Tamai H, Igaki K, Kyo E, et al. Initial and 6-month results of biodegradable poly-l-lactic acid coronary stents in humans. Circulation. 2000;102(4):399-404.
32. Douek PC, Correa R, Neville R, et al. Dose-dependent smooth muscle cell proliferation induced by thermal injury with pulsed infrared lasers. Circulation. 1992;86(4):1249-1256.
33. Colombo A, Karvouni E. Biodegradable stents: "fulfilling the mission and stepping away". Circulation. 2000;102(4):371-373.
34. Yamawaki T, Shimokawa H, Kozai T, et al. Intramural delivery of a specific tyrosine kinase inhibitor with biodegradable stent suppresses the restenotic changes of the coronary artery in pigs in vivo. J Am Coll Cardiol. 1998;32(3):780-786.
35. Ormiston JA, Webster MW, Armstrong G. First-in-human implantation of a fully bioabsorbable drug-eluting stent: the BVS poly-L-lactic acid everolimus-eluting coronary stent. Catheter Cardiovasc Interv. 2007;69(1):128-131.
36. Serruys PW, Ormiston JA, Onuma Y, et al. A bioabsorbable everolimuseluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet. 2009;373(9667):897-910.
37. Erbel R, Di Mario C, Bartunek J, et al. Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, nonrandomised multicentre trial. Lancet. 2007;369(9576):1869-1875.
38. Ho PM, Peterson ED, Wang L, et al. Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome. Jama. 2008;299(5):532-539.